Erin O'Brien

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

Researchers investigated the effects of this supplementation on cognitive function and disease severity in schizophrenia. Here’s what they found.

What is new in research on schizophrenia?

Take a look back at our recent coverage relating to our April content theme.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

What is new in research on alcohol use disorder?

In honor of this year’s National Alcohol Screening Day, here’s a look back at some recent coverage in Psychiatric Times about the diagnosis, treatment, and management of alcohol misuse.

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.

Write to us now to be part of our series focused on addiction and substance use disorders this month.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

Here are some updates from the world of psychiatry throughout the month of March.

What is new in research on bipolar disorder?

Here’s a look back at selections from our March content series on mood disorders.

Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

What is the Clubhouse model of psychosocial rehabilitation, and how can it benefit both patients and clinicians alike?

Expiring on May 20, 2024, this CME discusses how to apply several novel treatment approaches in the treatment of patients with bipolar depression. Here are 5 key takeaways.

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is new in research on COVID-19?

The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

What is spring mania, and what are some effective clinical strategies for addressing it?

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

What is new in research on child and adolescent psychiatry?

Take a look back at our recent coverage relating to our March content theme.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.